Citadel Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Citadel Advisors’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$22.8K	Sell	16,993 -161,179	-90%	-$250K	﹤0.01%	12640
2025 Q4	$289K	Buy	+178,172	New	+$386K	﹤0.01%	10231
2025 Q3	–	Sell	-60,624	Closed	-$89.7K	–	14343
2025 Q2	$89.7K	Buy	+60,624	New	+$94.9K	﹤0.01%	11417
2025 Q1	–	Sell	-149,698	Closed	-$540K	–	15739
2024 Q4	$540K	Sell	149,698 -654,764	-81%	-$1.58M	﹤0.01%	8380
2024 Q3	$1.75M	Buy	804,462 +74,610	+10%	+$259K	﹤0.01%	5795
2024 Q2	$2.93M	Buy	729,852 +5,951	+0.8%	+$40.9K	﹤0.01%	4598
2024 Q1	$7.52M	Buy	+723,901	New	+$8.32M	﹤0.01%	3338

Other funds holding MGX

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors's MGX Position: Q1 2026 in Review

Citadel Advisors reduced its Metagenomi Therapeutics (MGX) stake by 90% in Q1 2026, selling an estimated $250K and leaving 16,993 shares worth $22.8K. The position accounts for ﹤0.01% of the portfolio, ranked #12640.

Citadel Advisors first reported a position in MGX in Q1 2024 and has held it in 7 quarters since. The position peaked at $7.52M in Q1 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

Citadel Advisors held 16,993 shares of Metagenomi Therapeutics worth $22.8K as of Q1 2026.
Citadel Advisors sold 161,179 Metagenomi Therapeutics shares in Q1 2026, an estimated $250K.
Metagenomi Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12640 holding.
Citadel Advisors first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 7 quarters since.
Citadel Advisors's Metagenomi Therapeutics position peaked at $7.52M in Q1 2024.
48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.